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Abstract
Human ciliopathies are hereditary conditions caused by defects of proteins expressed at the
primary cilium. Among ciliopathies, Joubert syndrome and related disorders (JSRD), Meckel
syndrome (MKS) and nephronophthisis (NPH) present clinical and genetic overlap, being allelic at
several loci. One of the most interesting gene is TMEM67, encoding the transmembrane protein
meckelin. We performed mutation analysis of TMEM67 in 341 probands, including 265 JSRD
representative of all clinical subgroups and 76 MKS fetuses. We identified 33 distinct mutations,
of which 20 were novel, in 8/10 (80%) JS with liver involvement (COACH phenotype) and 12/76
(16%) MKS fetuses. No mutations were found in other JSRD subtypes, confirming the strong
association between TMEM67 mutations and liver involvement. Literature review of all published
TMEM67 mutated cases was performed to delineate genotype-phenotype correlates. In particular,
comparison of the types of mutations and their distribution along the gene in lethal versus non
lethal phenotypes showed in MKS patients a significant enrichment of missense mutations falling
in TMEM67 exons 8 to 15, especially when in combination with a truncating mutation. These
exons encode for a region of unknown function in the extracellular domain of meckelin.
Keywords
TMEM67; MKS3; Joubert syndrome; Meckel syndrome; congenital hepatic fibrosis; COACH
syndrome
INTRODUCTION
Human ciliopathies represent an expanding group of autosomal or X-linked disorders caused
by defects of proteins expressed at the primary cilium or its apparatus (Hildebrandt and
Zhou, 2007; Sharma et al., 2008). Primary cilia are microtubule-based structures found in
most tissues, that function as cellular sensors and control axonal migration and cell polarity
during development (Gerdes et al., 2009; Marshall, 2008). The wide expression pattern of
ciliary proteins well explains the multiorgan involvement seen in most ciliary disorders,
mainly implicating the central nervous system (CNS), retina, kidneys and liver (Lancaster
and Gleeson, 2009).
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There is striking clinical and genetic overlap among some ciliopathies, namely Joubert
syndrome and related disorders (JSRD; MIM# 213300), Meckel syndrome (MKS; MIM#
249000), and Nephronophthisis (NPH; MIM# 256100). These conditions are known to be
allelic at several gene loci, albeit genotype-phenotype correlations are only partly
understood (Lancaster and Gleeson, 2009). Among these genes, great interest has recently
arisen on TMEM67 (MIM# 609884) that encodes meckelin (Dawe et al., 2007; Smith et al.,
2006). This is a 995 aminoacid protein, with an extracellular N-terminus containing a signal
peptide and a cysteine rich domain, a transmembrane portion and an intracellular C-terminus
including a coiled-coil domain (Khaddour et al., 2007; Smith et al., 2006).
TMEM67 was first identified as causative of MKS (Smith et al., 2006), a lethal disorder
displaying CNS malformations (typically occipital encephalocele), multicystic kidneys,
ductal plate dysplasia with congenital hepatic fibrosis (CHF) and postaxial polydactyly
(Salonen, 1984; Salonen and Paavola, 1998). Large mutation screenings identified TMEM67
mutations in 23 of 195 (12%) MKS fetuses (Baala et al., 2007; Consugar et al., 2007;
Khaddour et al., 2007; Smith et al., 2006; Tallila et al., 2009), including some fetuses with
Meckel-like phenotypes. These lacked at least one MKS diagnostic criterion, and their brain
pathology often resembled the “molar tooth sign” (MTS) (Baala et al., 2007). The MTS
defines a specific constellation of cerebellar and brainstem abnormalities that is peculiar of
JSRD, another heterogeneous group of ciliopathies with CNS, retinal, renal and hepatic
manifestations (Valente et al., 2008). Within the JSRD spectrum, there is strong correlation
between TMEM67 mutations and the subgroup of JS plus liver involvement (COACH
syndrome; MIM# 216360), with an overall mutation frequency of 73% (Baala et al., 2007;
Brancati et al., 2009; Doherty et al., 2009).
Two additional TMEM67-related ciliopathies were recently delineated. Otto and
collaborators reported mutations in five of 62 (8%) probands with NPH and CHF (Otto et
al., 2009). Finally, TMEM67 was found mutated in two families with a peculiar association
of polycystic kidney (mimicking autosomal recessive polycystic kidney disease - ARPKD),
NPH, CHF and midbrain-hindbrain abnormalities within the MTS spectrum, defined as
ARPKD-like syndrome (Gunay-Aygun et al., 2009).
This extreme clinical heterogeneity associated with mutations in one and the same gene is
intriguing, and calls for the delineation of specific clinical-genetic correlates. The allelic
spectrum of TMEM67 is broad and includes missense, truncating and splice site mutations,
as well as rare multiexon deletions. A preliminary correlation has been observed between
truncating mutations and the occurrence of MKS, while missense mutations are more
frequently detected in association to less severe phenotypes such as COACH and NPH.
However, a systematic analysis of the phenotypic burden of TMEM67 mutations has not
been performed yet.
Here, we present the molecular screening of TMEM67 in two cohorts of patients, including
JSRD cases representative of all clinical subgroups, and MKS fetuses. We describe and
characterize 20 novel mutations, perform a detailed review of all published mutations and
discuss genotype–phenotype correlates.
MATERIALS AND METHODS
Patients
A total of 341 probands were analyzed. The first group included 265 probands with
clinically and neuroradiologically confirmed diagnosis of JSRD. Detailed clinical data were
obtained by referring clinicians of the International JSRD Study Group through a
standardized questionnaire, allowing to assign patients to the following subgroups: pure JS
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(n=101), JS plus retinopathy (n=51), JS plus renal disease (n=11), cerebello-oculo-renal
syndrome (n=80), JS plus liver disease (n=10), oro-facio-digital syndrome type VI (n=12).
The second group included 76 fetuses diagnosed with MKS according on established criteria
(Salonen, 1984). Pregnancies were terminated after genetic counseling, in accordance with
local laws. Subjects were recruited worldwide and collected under approved institutional
human subject protocols. Written informed consent was obtained from all families. A
number of these patients have been included in previous mutational screenings of other
JSRD/MKS causative genes, while probands already tested for TMEM67 and previously
described (Brancati et al., 2009; Khaddour et al., 2007) have been excluded from the study.
Mutational analysis
Exons and exon-intron junctions of the TMEM67 gene were searched for mutations adopting
two distinct strategies. In the cohort of JSRD patients, the High Resolution Melting
technique (HRM) on a LightCycler® 480 Real-Time PCR system (Roche Applied Science)
was used to analyze DNA samples of both parents of each affected proband, in order to
overcome the limitations of HRM technique in discriminating homozygous mutations
(Wittwer, 2009). Each PCR reaction included 15-25 ng of genomic DNA and High
Resolution Master Mix (Roche Applied Science), which contained FastStart Taq DNA
polymerase, reaction buffer, dNTPs mix and ResoLight Dye. MgCl2 and each primer were
added to 3mM and 0.2μM final concentrations respectively. Primers have been reported
previously (Brancati et al., 2009). PCR conditions included an initial denaturation at 95°C
for 10 min followed by 45 cycles of denaturation (95°C for 15 s), annealing (primer
dependent for 15 s) and extension (72°C for 15 s), with a final extension at 72°C for 2 m.
After PCR, a post-amplification melting curve program was initiated by heating to 95°C and
cooling to 40°C for 1 min each, and then increasing the temperature to 95°C while
continuously measuring fluorescence at 25 acquisitions per degree. Melting curves were
analyzed by LightCycler 480 Gene Scanning software (Roche Applied Science). Samples
with significant difference in melting profiles and corresponding proband samples
underwent direct bidirectional sequencing using the Big Dye Terminator Chemistry and an
ABI 3100 Capillary Array Sequencer (Applied Biosystems). In the cohort of MKS patients,
bidirectional sequencing was performed as previously described (Khaddour et al., 2007).
Bioinformatic analysis
DNA mutation numbering was based on cDNA sequence, +1 being the first nucleotide of
the ATG translation initiation codon in the reference sequence. Mutation description was
checked with Mutalyzer software (http://www.humgen.nl/mutalyzer/1.0.1). Prediction of the
possible impact of missense variants on the function of meckelin protein was obtained with
PolyPhen software (http://genetics.bwh.harvard.edu/pph/), while HSF
(http://www.umd.be/HSF) was used to evaluate the potential impact of nucleotide changes
on splicing. Multiple sequence alignments of the human meckelin protein and its
orthologues were generated using the ClustalW program (http://www.ebi.ac.uk/clustalw/).
Accession numbers are as follows: human TMEM67 mRNA sequence: NM_153704.5;
meckelin protein sequence: Homo sapiens NP_714915.3 or ENSP00000314488; Macaca
mulatta ENSMMUP00000007350; Rattus norvegicus ENSRNOP00000021839; Mus
musculus ENSMUSP00000052644; Gallus gallus ENSGALP00000025642; Tetraodon
nigris GSTENP00034026001; Drosophila melanogaster FBpp0112166; Caenorhabditis
elegans F35D2.4. Mutation frequencies were compared using a two-tail Fisher's exact test,
with correction for multiple tests when applicable. Significance was set at p<0.05.
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RESULTS
The molecular analysis identified 33 distinct mutations (20 novel and 13 previously
reported) in 20 out of 341 families. Overall, 12 mutations were truncating (including
frameshift and nonsense), three affected 5' or 3' canonical splice-sites and 18 were missense.
All mutations segregated with the disease in familial cases. None of the nine newly
identified missense mutations were found in 200 control chromosomes, and alignment with
meckelin orthologues showed all affected residues to be conserved among different species
(Figure 1). Detailed clinical features of mutated JSRD patients and MKS fetuses are
summarized in Tables 1 and 2.
Pathogenic mutations in JSRD
Among the 265 JSRD patients, TMEM67 compound heterozygous mutations were identified
in 8 out of 10 (80%) probands with a phenotype of JS plus liver disease. Twelve mutations
were missense, three truncating and one affected splicing. Liver involvement varied from a
clinically mild picture of asymptomatic but constant elevation of liver enzymes to more
severe presentations leading to liver insufficiency and biopsy-proven CHF. Six of the eight
probands had mono-or bilateral colobomas, while the affected sister of one proband with
bilateral colobomas had optic nerve hypoplasia. Only one patient (COR212) presented post-
axial polydactyly of the four limbs and infantile NPH, that progressed to chronic renal
failure at age six months. Several patients were too young at latest examination to rule out
the possibility that some of them would develop juvenile NPH later in life. Biallelic
mutations were not detected in any of the 255 patients representative of the other JSRD
phenotypes.
Pathogenic mutations in MKS
In this group, we identified 18 distinct mutations in 12 out of 76 (16%) MKS fetuses, either
in homozygosity (n=5) or compound heterozygosity (n=7). Of these mutations, seven were
missense (one recurrent in two fetuses), nine truncating and two affected splice sites. Cystic
kidneys were diagnosed in all fetuses, while all but two sibs had the ductal plate
malformation of the liver. Polydactyly was never recorded. Clinical variability was observed
with respect to CNS malformations, with encephalocele, Dandy-Walker malformation and
cerebellar vermis hypo/aplasia being variably present. Genitalia abnormalities (including
bicornate uterus or vaginal septum), and tetralogy of Fallot were recorded in single patients.
DISCUSSION
Here we present the results of the largest TMEM67 screening so far reported in JSRD/MKS,
leading to the identification of twenty novel mutations. In the JSRD group, we found
mutations in the great majority of patients with liver involvement, ranging from the full-
blown COACH syndrome phenotype (with proven hepatic fibrosis at liver biopsy) to milder
presentations variably including hepatomegaly, elevation of liver enzymes and abnormal
liver imaging. Along with our previously reported cases (Brancati et al., 2009) and with
those published by Doherty and coworkers (Doherty et al., 2009), this brings the TMEM67
mutation frequency in JS with liver involvement to 70% (32 out of 46), representing to date
the strongest gene-phenotype correlate among JSRD subgroups (Valente et al., 2008).
The proportion of MKS fetuses mutated in TMEM67 is much lower. We identified
mutations in 12 out of 76 MKS probands, bringing the overall mutation frequency to 13%
(35 out of 271 tested fetuses) (Baala et al., 2007; Consugar et al., 2007; Khaddour et al.,
2007; Smith et al., 2006; Tallila et al., 2009). Yet, TMEM67 remains to date one of the most
commonly mutated gene in MKS, along with MKS1 and CC2D2A. Yet, at difference from
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TMEM67, both these genes present mutational hotspots explaining a large proportion of
mutated cases (Tallila et al., 2009).
As previously reported, we observed that the feature most strikingly associated with
TMEM67 mutations, and in fact shared by all mutated patients regardless of other
symptoms, is congenital liver involvement. In fact, Otto and collaborators reported
TMEM67 mutations in 8% NPH probands with CHF, but failed to identify mutations in 105
NPH patients lacking liver disease. Similarly, the two TMEM67-mutated families with
ARPKD-like syndrome also presented CHF (Gunay-Aygun et al., 2009; Otto et al., 2009).
This congenital liver disease originates by a developmental defect, the ductal plate
malformation, resulting from failed remodeling of the ductal plate, that leads to bile duct
proliferation and in many cases to overt CHF (Desmet, 1992). Defects in cilia formation and
abnormal hepatic cell differentiation have been observed in the liver of some MKS fetuses
(Clotman et al., 2008). Indeed, meckelin is known to be required for the correct cilium
assembly, and it was also suggested to play a role in signal transduction at developmental
stages preceding cilia formation in the liver (Clotman et al., 2008; Dawe et al., 2007).
However, it is interesting to note that neither the rat (wpk) nor the mouse (bpck) models of
MKS3 present any sign of liver involvement, while being affected by a rapidly progressive
renal, retinal and neurological phenotype (Cook et al., 2009; Tammachote et al., 2009).
Thus, the essential role of meckelin in liver development appears to be restricted to the
human species, possibly representing a recently acquired function during the evolutionary
process.
We failed to identify TMEM67 mutations in any of 255 JSRD patients belonging to the other
clinical subgroups, arguing against a major role of the gene in these phenotypes. In fact, out
of about 600 JSRD families tested so far, only five with TMEM67 mutations were reported
that did not show any sign of hepatic involvement, confirmed by either long-term follow-up
or appropriate liver investigations in four of them (Baala et al., 2007; Doherty et al., 2009;
Otto et al., 2009). These patients may share yet unknown protective factors against the
development of congenital liver disease, although the possibility that they harbor a peculiar
combination of TMEM67 alleles giving rise to a more benign phenotype is also possible. Of
note, the allelic combinations are unique to these five families, and two of them share a
substitution of the same proline residue in position 82 (Doherty et al., 2009). Functional
studies in different cell types will help establish the different tissue-specific pathogenicity of
such mutations.
In the present work, we report the identification of 20 novel mutations, raising to 87 the
number of distinct pathogenic TMEM67 changes so far reported (Baala et al., 2007; Brancati
et al., 2009; Consugar et al., 2007; Doherty et al., 2009; Gunay-Aygun et al., 2009;
Khaddour et al., 2007; Otto et al., 2009; Smith et al., 2006; Tallila et al., 2009). Of these, 19
recurred in two or more families while the others were reported in single cases. Overall,
mutations are scattered throughout the entire gene with only two exons spared (exon 4 and
28). Mutations within eight out of 28 exons (2, 6, 8, 11, 13, 15, 18, 24) captured more than
60% of the TMEM67 allelic spectrum, suggesting that these exons should be prioritized
when performing molecular analysis (Figure 2).
Interestingly, a differential distribution of mutations along the gene in lethal (MKS) versus
non-lethal (JSRD, NPH or ARPKD-like) phenotypes can be observed, in particular when
considering missense mutations. In fact, in MKS patients most missense mutations (18/24,
75%) cluster within exons 8 to 15, encoding the extra-cellular region of meckelin that
follows the cystein-rich domain. Conversely, in non lethal-phenotypes only one third of
missense mutations are found within exons 8-15 (21/61, 34%; p=0.001) being sparse along
the entire coding sequence of the gene (Figure 3).
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In line with these findings, we also observed different combinations of mutation types
between lethal and non-lethal phenotypes (Figure 4). In order to assess the statistical
significance of this observation, we decided to exclude splice site mutations (which effect on
protein function is difficult to predict) and considered only 23 lethal versus 33 non-lethal
cases carrying either combination of truncating and missense mutations (Figure 4, left side).
Two truncating mutations were observed in about one third of MKS patients (8/23, 35%) but
in none of the patients with non-lethal phenotypes (p=0.001). A combination of a truncating
with a missense mutation was detected in a similar proportion of lethal and non-lethal cases
(6/23 vs 9/33, 26% vs 28%), yet the position of the missense mutation in the gene varied
significantly in the two groups, falling within exons 8-15 in 66% of MKS cases, but never in
non-lethal cases (p=0.01). Homozygous or compound heterozygous missense mutations
were detected in 9 (39%) lethal and 24 (73%) non-lethal families respectively (p=0.045). At
least one missense mutation affecting exons 8 to 15 was detected in all 9 MKS and in 17/24
(71%) of non-lethal cases, although this difference did not reach statistical significance.
In line with these findings, we also observed different combinations of mutation types
between lethal and non-lethal phenotypes (Figure 4). In order to assess the statistical
significance of this observation, we decided to exclude splice site mutations (which effect on
protein function is difficult to predict) and considered only 23 lethal versus 33 non-lethal
cases carrying either combination of truncating and missense mutations (Figure 4, left side).
Two truncating mutations were observed in about one third of MKS patients (8/23, 35%) but
in none of the patients with non-lethal phenotypes (p=0.001). A combination of a truncating
with a missense mutation was detected in a similar proportion of lethal and non-lethal cases
(6/23 vs 9/33, 26% vs 28%), yet the position of the missense mutation in the gene varied
significantly in the two groups, falling within exons 8-15 in 66% of MKS cases, but never in
non-lethal cases (p=0.01). Homozygous or compound heterozygous missense mutations
were detected in 9 (39%) lethal and 24 (73%) non-lethal families respectively (p=0.045). At
least one missense mutation affecting exons 8 to 15 was detected in all 9 MKS and in 17/24
(71%) of non-lethal cases, although this difference did not reach statistical significance.
Taken together, these findings suggest that missense mutations in exons 8 to 15 might have
a more disruptive effect on the protein's function. One possibility is that a relevant subset of
these mutations could affect splicing either by creating or disrupting splice sites or by
affecting exonic splice enhancers/silencers, as already shown for other TMEM67 coding
variants (Baala et al., 2006; Kaddhour et al., 2007). Yet, we could not detect any significant
differences between mutations falling within and outside exons 8 to 15 on their in silico
predicted effects on splicing mechanisms. An alternative possibility is that the extracellular
region encoded by exons 8 to 15 plays an crucial role for the protein's function, thus
explaining the increased pathogenicity of missense mutations altering the aminoacidic
structure of this region. To address this hypothesis, we have obtained PolyPhen PSIC scores
for all reported missense mutations. Although the vast majority are predicted to be
damaging, no significant differences were found in the frequency of benign, possibly and
probably damaging changes falling within or outside exons 8-15, and the mean PSIC score
obtained for this exon cluster was similar to that obtained for the remaining exons (data not
shown). However, it must be noted that PolyPhen prediction is based on empirical rules
applied to the amino acid sequence, phylogenetic profile scores, and calculation of structural
parameters, and thus it is most accurate when the protein's structure is well characterized.
Conversely, no information is available on the functional role of the region encoded by
exons 8 to 15; moreover, we attempted to perform bioinformatic modelling of this region but
could find no obvious close or even remote homologies with any known protein domain.
This suggests a limited power in predicting pathogenicity of mutations affecting this region,
and also implies a potential novel and unique role in meckelin function. Indeed, subcellular
localization experiments showed that the c.1127A>C mutation within exon 11 (p.Q376P)
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affected the ability of meckelin to localize at the cell surface, causing retention in the
endoplasmic reticulum and consequent loss of function (Dawe et al., 2007). Detailed
functional studies are needed to characterize the physiological function of this meckelin
region and the disruptive effect of missense mutations.
The different pathogenic load of TMEM67 mutations is also suggested by the fact that each
combination of two given mutations is unique to a given ciliopathy, the only exception being
represented by two families compound heterozygous for the two missense changes p.M252T
and p.C615R, presenting with MKS and COACH syndrome respectively (Otto et al., 2009;
Tallila et al., 2009). In this case, it is plausible to speculate that mutations or polymorphic
variants located in other (ciliary) genes may play a relevant role as genetic phenotypic
modifiers. This hypothesis, already put forward for variants in other ciliary genes (Khanna et
al., 2009; Tory et al., 2007), opens novel enticing research perspectives to understand the
increasing complexity of ciliary disorders.
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Figure 1.
Conservation across species of novel TMEM67 missense mutations. *indicates affected
residues
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Figure 2.
Distribution across the TMEM67 gene of truncating, splice site and missense mutations so
far reported.
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Figure 3.
Distribution across the TMEM67 gene of missense mutations so far identified in patients
with lethal (MKS) and non-lethal (JSRD, NPH and ARPDK-like) phenotypes.
Correspondence between TMEM67 exons and predicted meckelin domains is depicted at the
bottom. SP: signal peptide; CR: cystein rich domain; TM1-2-3: transmembrane segments;
CC: coiled coil domain; the dashed box indicates the extracellular region of meckelin
encoded by exons 8 to 15.
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Figure 4.
Combination of mutation types so far reported in patients with lethal and non-lethal
phenotypes. Statistical comparison has been performed only for the three groups on the left
(two truncating mutations, truncating + missense, two missense mutations). Trunc:
truncating (frameshift and nonsense mutations); miss: missense; splice: splice-site affecting
mutation. *p<0.05
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